Agents and Actions

, Volume 32, Issue 1–2, pp 119–121 | Cite as

Zymosan inflammation: A new method suitable for evaluating new antiinflammatory drugs

  • K. Gadó
  • G. Gigler
Papers Given at the 12th European Workshop on Inflammation, Halle, Germany, May 30–31, 1990 Free Communications


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    J. P. Tarayre, A. Delhon, M. Aliaga, M. Barbara, F. Bruniquel, V. Caillol, L. Puech, N. Consul and J. Tisne-Versailles,Pharmacological studies on zymosan inflammation in rats and mice. 1: Zymosan-induced paw oedema in rats and mice. Pharmacol. Res.21, 375–384 (1989).PubMedGoogle Scholar
  2. [2]
    N. S. Doherty, P. Poubelle, P. Borgeat, T. H. Beaver, G. I. Westrich and N. L. Schrader,Intraperitoneal injection of zymosan in mice induces pain, inflammation and the synthesis of peptidoleukotrienes and prostaglandin E 2. Prostaglandins30, 769–789 (1985).CrossRefPubMedGoogle Scholar
  3. [3]
    C. A. Winter, E. A. Risley and G. W. Nuss,Carrageenin-induced edema in hind paw of rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med.111, 544–547 (1962).Google Scholar
  4. [4]
    R. Vinegar, W. Schreiber and R. Hugo,Biphasic development of carrageenin edema in rats. J. Pharm. Exp. Ther.166, 96–103 (1969).Google Scholar
  5. [5]
    J. R. Beetens, W. Loots, Y. Somers, M. C. Coene and F. de Clerck,Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem. Pharm.35, 883–891 (1986).CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1991

Authors and Affiliations

  • K. Gadó
    • 1
  • G. Gigler
    • 1
  1. 1.EGIS PharmaceuticalsBudapestHungary

Personalised recommendations